Japan Continuous Glucose Monitoring Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Japan Continuous Glucose Monitoring Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

During the forecast period, the Japan Continuous Glucose Monitoring Devices Market is set to witness a CAGR of more than 14%.

COVID-19 disrupted all aspects of the diabetes industry worldwide and in Japan. Several companies faced disruptions in supply and distribution channels across the country since most of the CGM device components were manufactured outside of Japan. This created a gap between the supply and demand of the devices wherein the limited inventory was available. As a result, the impact of COVID-19 was considerable concerning access to a persistent continuum of care among the Japanese diabetic population. For instance, as per the primary insights, "Almost all Japanese diabetes patients visited their hospital or clinic every 2-3 months despite the COVID-19 pandemic. However, HCPs had limited communication with their patients, which impacted the consumer base and made it difficult to gain new users. In addition, the companies dealing in diabetes care were shut down, and patients visiting hospitals/clinics were unable to provide the product's information to HCPs" (Registered Nurse, Diabetes Care Japan, Lifescan).

Diabetes is a chronic condition marked by high blood glucose levels. It is caused either by the inability to produce insulin (a hormone made by the pancreas to keep blood glucose levels in range) or by the body not being able to use insulin effectively, or both.

Type 1 diabetic patients need to take insulin throughout their lives and maintain a healthy diet and regular physical exercise. Whereas Type 2 diabetic patients need to eat healthily, be physically active, and test their blood glucose level, and may also need to take oral medication and insulin to control the glucose level in their blood. The need for monitoring blood glucose levels is on the rise among diabetic patients, mainly to avoid complications, such as cardiovascular diseases, stroke, blood disorders, blindness, and kidney disorder, among others.

Various CGM devices are available in the japan market. Dexcom develops and manufactures the current-generation G6 CGM. Terumo markets the G6 in Japan. The Dexcom G6 system features a wearable sensor attached to a user’s abdomen. It automatically transmits glucose measurements every five minutes to a monitor or smart device with a dedicated application. Users can check their real-time glucose values and trends through a visualized graph. Additionally, G6 notifies users when glucose measurements fall outside a pre-set target range. It also sends alerts upon predictions of hypoglycemia occurring in 20 minutes.

Transmitter is a component of the sensor that sends the blood glucose levels to the reader, receiver, or smartphone app. Receivers are the devices that receive data from the transmitters and display the results on different user interfaces. The way these components of CGM device work varies as per the manufacturer. These devices can be visible and may be required to be placed on the skin. The transmitter batteries may be rechargeable or disposable. The market segment is expected to witness growth as a result of the growing use of CGM devices among the diabetic population, growing underlying causes resulting in diabetes, market availability of the products, advantages offered by these durables, and surge in awareness regarding the use of CGM devices among the Japanese population.

Diabetes has been identified as a healthcare priority by Japan's Ministry of Health, Labour, and Welfare. The high prevalence of type 2 diabetes is associated with a significant economic burden. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.

The Type 1 diabetes Population in Japan is expected to increase with a CAGR greater than 0.4% over the forecast period.

There has been a rapid growth in diabetes in Japan. As per IDF 2021 estimates, 11 million adults in Japan have diabetes. The objectives of diabetes management are to improve metabolic dysfunctions resulting from hyperglycemia to prevent the development or progression of diabetic complications and conditions associated with diabetes and to enable affected individuals to maintain their quality of life and life expectancy at a level comparable to those in healthy individuals.

The JDS has set an HbA1c control target of ‘less than 7.0%’. At the same time, treatment guidelines developed by the JDS recommend that the general treatment target for HbA1c should be individualized according to treatment risks and patient characteristics.

As the prevalence of diabetes increases, the condition itself and the associated complications are generating a considerable and increasing economic burden on the healthcare system and society. Japan is reflecting this trend, facing a growing prevalence of T2D and T1D population, with an overall diabetes prevalence rate of 9.7%, as per the data published by a Kobe University study in February 2023. The potential opportunities that diabetes could generate, both in a present and future setting, are profitable for all stakeholders, ultimately creating numerous possibilities for the companies operating within the market.

Hence, the demand for continuous glucose monitoring devices and their adoption rate is also increasing. These factors are expected to drive the market studied.​

The Japan Continuous Glucose Monitoring Devices Market is highly consolidated. The Market leaders such as Dexcom, Abbott, and Medtronic are focusing on product launches and technological collaboration to increase their foothold in the market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support